WuXi Biologics Achieved Record Growth and Profitability in 2021

Banner Year for Commercial Manufacturing Revenue Increased by 83.3% Y-o-Y to RMB10,290.1 Million Gross Profit Increased by 90.6% Y-o-Y to RMB4,828.9 Million...

Related Keywords

Germany ,Japan ,Wuppertal ,Nordrhein Westfalen ,United States ,Wuxi ,Jiangsu ,China ,Hong Kong ,Singapore ,Henan ,Ireland ,Hangzhou ,Zhejiang ,Chinese ,Chris Chen ,Group Wuxibody ,Shareholders Of The Company ,Given The Group ,Manufacturing Organization ,Contract Research ,Prnewswire Wuxi Biologics Cayman Inc ,Innovative Technology Platforms ,Hong Kong Listed Companies ,Banner Year ,Commercial Manufacturing ,Profit Increased ,Profit Grew ,Net Profit Rose ,Backlog Grew ,Model Created Sustainable Long Term ,Strategies Drove Significant Revenue ,Projects Added ,Projects Reached ,Projects Increased ,Commercial Manufacturing Revenue Increased ,Much Potential ,Quality System Re Verified ,Supply Chain ,Safeguard Project Execution ,Starting Any Project ,Global Presence ,Grew Talent Pool ,Key Talent Retention ,Net Profit Attributable ,Net Profit ,Wuxi Vaccines ,Wuxi Apptec ,Stock Code ,Dual Sourcing ,Big Pharma ,Small Pharma ,Institutional Investor ,Corporate Governance ,Kong Corporate Governance ,Industry Top Rated Company ,Wuxi Biologics ,Drug Product ,Drug Substance ,Pfizer China ,Chinese Hamster Ovary ,Henan Province ,Reporting Period ,Twelve Months Ended Dec ,Profit Margin ,Profit Attributable ,